Trailing Twelve Months Revenue Growth: Apimeds Pharmaceuticals (APUS)

Brandmark of Apimeds Pharmaceuticals US (APUS)

Apimeds Pharmaceuticals (APUS) develops patent-protected neurological treatments, which stabilizes cash flows. Joint research with clinics on the application of bee venom expands joint therapy. Year-over-year sales dynamics over the last 12 months TTM demonstrate the impact of these factors, where the 0.00 mark characterizes this parameter. However, scaling protein development is leading to increased testing costs.

Apimeds Pharmaceuticals US (APUS): Revenue Growth YoY (Last 12 Months) from 11/23/2025 to 11/17/2026

Summary analytical data breakdowns for Apimeds Pharmaceuticals, Inc. (APUS)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:APUS Apimeds Pharmaceuticals US
Original product of Apimeds Pharmaceuticals US

The unique properties of Apimeds Pharmaceuticals (APUS) biocomponents ensure a steady expansion of the client base within the neurology segment. GURU.Markets tools calculate the year-over-year sales growth percentage for TTM as the difference in revenue between the current twelve months and the same prior period. This price action on the chart reflects the actual speed of business scaling. The positive trend confirms the resilience of sales to external shocks. The growth of this metric enhances the fundamental attractiveness of the asset.